SSY Group (HKG:2005) recorded an attributable profit of HK$399 million in the first nine months, down 57% from a year prior, a Tuesday Hong Kong bourse filing said.

Turnover for the three quarters fell 32% to roughly HK$3.1 billion, mainly due to a drop in the sales volume of intravenous infusion solution and turnover from ampoule injections.